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Early recognition of vulnerable patients is an important issue for stroke prevention. In our study, a multiscore analysis of various
biomarkers was performed to evaluate its superiority over the analysis of single factors. Study subjects (n = 110) were divided into
four groups: asymptomatic patients with stable (n = 25) and unstable (n = 36) plaques and symptomatic patients with stable
(n = 13) and unstable (n = 36) plaques. Serum levels of MMP-1, -2, -3, -7, -8, -9, TIMP-1, -2, TNF-α, IL-1b, and IL-6, -8, -10, -12
were measured. Multi-score analysis was performed using multiple receiver operating characteristics (ROC) and determination of
appropriate cutoﬀ values. Signiﬁcant diﬀerences between the groups were observed for MMP-1, -7, -9 and TIMP-1 in serum of the
study subjects (P<0.05). Multiple biomarker analysis led to a signiﬁcant increase in the AUC (area under curve). In case of plaque
instability, positive predictive value (PPV) for up to 86.4% could be correctly associated with vulnerable plaques. Thus, multiscore
analysis might be preferable than the use of single biomarkers.
1.Introduction
Early recognition of rupture-prone atherosclerotic lesions
in patients with high-graded carotid artery stenosis is an
important clinical issue to prevent ischemic stroke [1–5].
Various pathophysiological mechanisms are responsible for
the plaque progression and vulnerability such as degradation
of extracellular matrix components especially by matrix
metalloproteinases (MMPs), intensiﬁed inﬂammatory reac-
tion, and neovascularisation [3, 5–7]. These features are the
main reason for plaque rupture and consequent neurological
symptoms. Thus, MMPs and inﬂammatory factors might
also serve as possible markers for patients with unstable
high-graded carotid artery stenosis [2, 8–16]. However, the
data that have been achieved up to date are not consistent.
Some studies investigated patients with symptomatic versus
asymptomatic carotid stenosis or patients with or without
emboli [12, 14–17]. Other researchers compared stable
versus unstable plaques [2, 18, 19]. Furthermore, only
very few investigations evaluated the usefulness of multiple
biomarkers to predict rupture-prone atherosclerotic lesions
[2, 17, 20, 21].
The aim of this work was the comparison of results of
multiple analyses of various relevant biomarkers in patients
withstableversusunstablecarotidplaquesandinindividuals
with or without neurological symptoms to evaluate whether
multiple-score evaluation is superior to the analysis of single
factors.
2.MaterialsandMethods
2.1. Study Patients. The retrospective study consisted of 110
consecutive patients with high-grade carotid artery stenosis
>70% (determined by ultrasound) [22], intended for carotid
endarterectomy (CEA). All patients underwent a detailed
neurological examination by a neurologist, and the carotid
plaques were analysed by means of histology to divide the
study subjects into four groups: (1) asymptomatic patients
with stable plaques (n = 25); (2) asymptomatic patients2 International Journal of Vascular Medicine
with unstable plaques (n = 36); (3) symptomatic patients
with stable plaques (n = 13); (4) symptomatic patients
with unstable plaques (n = 36). The study was performed
accordingtotheGuidelinesoftheWorldMedicalAssociation
Declaration of Helsinki.
2.2. Histological Characterisation of Carotid Artery Lesions.
The excised carotid plaques were ﬁxed in formalin, separated
into segments of 3-4mm, and embedded in paraﬃn. From
eachsegmentsectionsof2-3μmwerepreparedandroutinely
stained with hematoxylin/eosin (HE) and Elastin van Gieson
(EvG) to assess the morphological and histological features
of each plaque. Stained specimens were analysed by light
microscopy from two independent and experienced inves-
tigators blinded for the study groups. In accordance with
our own expertise and the study of Rothwell and Redgrave
[18,19],appropriateselectionintostableorunstableplaques
was performed.
2.3. Immunohistochemistry (IHC). Immunohistochemical
analyses were performed on formalin-ﬁxed, paraﬃn-em-
bedded carotid plaques. Primary antibodies against follow-
ing antigens were used: CD68 (macrophages/monocytes;
Dako), CD45 (inﬂammatory inﬁltrates; Novocastra, UK),
smooth muscle cell actin (Dako, Hamburg, Germany), and
Factor VIII (endothelial cells; Dako). Visualisation was
performed with Peroxidase/DAB ChemMate Detection Kit
(Dako).
2.4. Blood Sample Analyses. Blood sampling was performed
from all patients immediately prior to surgical interven-
tion. MMPs and TIMPs were quantiﬁed in serum samples
using ELISA assays from R&D System (Quantikine human
MMPs and TIMPs kit; Wiesbaden-Nordenstadt, Germany)
according to the manufacture’s protocols. The colour devel-
opment was determined by multiplate reader Mithras LB940
(BertholdTechnologies,BadHerrenalb,Germany)at450nm
with correction at 570nm. Inﬂammatory markers were
analysed using Cytometric Bead Array (BD Biosciences, San
Jose, CA, USA). Fibrinogen activity was determined by the
Clauss method (Dade Behring, Schwalbach, Germany). The
hsCRP (high sensitivity CRP) was determined by ELISA
assay (Life Diagnostics; West Chester, PA, USA. Additional
clinical blood parameters were measured in laboratories of
our clinical chemistry.
2.5. Statistical Analyses. Statistical analyses were performed
with SPSS for Windows version 17.0. (SPSS Inc., Chicago, IL,
USA).Valuesofcontinuousvariableswereexpressedasmean
± standard deviation (SD). Kolmogorov-Smirnov test was
usedtoassessnormaldistribution.One-wayANOVAtestwas
applied for comparison between the groups. Correlations
between the single factors were quantiﬁed by Spearman’s
rank correlation coeﬃcient. Receiver operating character-
istics (ROC) analysis was applied to evaluate the optimal
positive and negative predictive value of each prognostic
marker and their combinations. DeLong and Clarke-Pearson
approach was used to compare ROC curves to provide the
best statistical evidence [23]. All statistical comparisons were
performed two sided in sense of an exploratory data analysis
using P<0.05, P<0.01, and P<0.001 as level of
signiﬁcance.
3. Results
3.1. Patient Characteristics. The demographic data of all
patients are summarised in Table 1. All groups were well
matched, without any signiﬁcant diﬀerences with regard
to patient epidemiology, associated diseases, or medication.
The average age of the study population was 69 years
(range 59 to 79). The majority of patients had hypertension
(>87%) and about one-third suﬀered under accompanying
coronary heart disease. All patients with the exception of one
individual received ASA or clopidogrel, and more than half
of the study subjects were on statins.
3.2.SerumLevelsofMMPs,TIMPs,andInﬂammatoryFactors.
The results of blood serum analysis are summarised in
Table 2. Signiﬁcant diﬀerences between the groups were
observed only for MMP-1, -7, -9, and TIMP-1. (P = 0.047,
0.005, 0.028, and 0.044, resp.). Tendency was observed also
for MMP-8; the diﬀerence was, however, not statistically
signiﬁcant. In many cases, increased level of various inﬂam-
m a t o r yf a c t o r sw a sf o u n di nt h eg r o u po fs y m p t o m a t i c
patients with unstable carotid plaques. However, again the
values were not statistically diﬀerent.
3.3. Correlation Analysis. Regarding causal relationships
between the individual factors analysed in our study, we
performed correlation analysis between MMPs, TIMPs, and
all the inﬂammatory factors tested in blood of the patient
cohort (Table 3). Most correlations were found between
individualMMPsandTIMPs:thelevelsofMMP-1correlated
signiﬁcantly with MMP-7 and TIMP-1 (P<0.001 and
P<0.05, resp.), MMP-2 with TIMP-2 (P<0.001),
MM-3 with MMP-7 (P<0.05), MMP-7 with TIMP-1
(P<0.001), MMP-8 with MMP-9 and TIMP-1 (P<0.001
and P<0.05, resp.), and TIMP-1 with TIMP-2 (P<0.001).
Furthermore, signiﬁcant correlations were observed between
someinﬂammatoryfactorsandMMPs:IL-1β correlatedwith
MMP-9 (P<0.0 5 ) ,I L - 6w i t hM M P - 7a n d- 8( P<0.001
and P<0.01, resp.), and IL-12 with MMP-2 (P<0.01); the
amountofleukocyteswasrelatedtoMMP-8and-9(P<0.01
and P<0.001, resp.) and ﬁbrinogen to MMP-7, -8, and -9
(P<0.05 and P<0.001, resp.).
3.4. Multiple ROC Curve Analysis. To evaluate whether the
individual factors and their appropriate combination in
blood of the study patients can be associated with carotid
plaque instability or neurological symptoms, ROC curve was
designed accordingly. Furthermore, multiple analysis was
performed to assess the validity of biomarkers to further
improve the predictability. In accordance with the above-
described analyses between the study groups, only factors
with signiﬁcant diﬀerences were involved in the ROC curve
analysis: MMP-1, -7, -9, and TIMP-1. The area under curveInternational Journal of Vascular Medicine 3
Table 1: Patients characteristics.
Asym/stable∗ Asym/unstable Sym/stable∗ Sym/unstable P value∗∗
n = 25 of 110 n = 36 of 110 n = 13 of 110 n = 36 of 110
Age (years) 68.8 ±9.76 7 .6 ±7.77 1 .6 ±7.86 8 .6 ±9.6 0.210
Sex (male/female) 14/11 29/7 9/4 22/24 0.140
Associated diseases
Coronary heart disease 40.0 46.8 27.3 30.3 0.491
Hypertension 90.5 87.5 90.9 78.8 0.586
Chronic kidney disease 4.8 9.3 9.1 3.1 0.724
Diabetes mellitus 14.3 37.5 27.3 18.2 0.106
Medication
ASA/clopidogrel 100.0 96.8 100.0 100.0 0.573
Beta-blockers 65.0 74.2 72.7 65.6 0.860
ACE inhibitors 35.0 51.6 45.4 46.9 0.322
Statins 70.0 54.8 54.5 64.1 0.212
Age: mean ± standard deviation; all other values are in % of the study subjects within the each group; ASA: Acetyl salicylic acid.
∗Asym: asymptomatic patients, Sym: symptomatic patients.
∗∗One-way ANOVA (analysis of variance) was used.
Table 2: Levels of various clinical factors in blood serum of study subjects.
Asym/stable Asym/unstable Sym/stable Sym/unstable P value∗∗
n = 25 of 110 n = 36 of 110 n = 13 of 110 n = 36 of 110
MMP-1 [ng/μL] 2.4 ±1.84 .4 ±3.84 .1 ±2.83 .9 ±2.7 0.047
MMP-2 [ng/μL] 257 ±81 261 ±91 237 ±62 269 ±81 0.672
MMP-3 [ng/μL] 14.1 ±5.51 4 .8 ±8.71 4 .6 ±4.11 3 .4 ±4.7 0.279
MMP-7 [ng/μL] 7.1 ±3.21 0 .1 ±4.71 1 .6 ±5.21 0 .7 ±4.1 0.005
MMP-8 [ng/μL] 11.3 ±9.11 1 .2 ±11.51 0 .2 ±6.51 7 .1 ±19.5 0.212
MMP-9 [ng/μL] 192 ±65 178 ±74 210 ±66 231 ±80 0.028
TIMP-1 [ng/μL] 139 ±41 161 ±70 167 ±47 182 ±59 0.044
TIMP-2 [ng/μL] 65.0 ±22.26 9 .0 ±29.16 1 .1 ±29.67 4 .5 ±41.7 0.552
TNF-α [pg/μL] 2.5 ±0.83 .2 ±1.22 .3 ±1.43 .3 ±1.5 0.134
IL-1β [pg/μL] 1.1 ±1.42 .1 ±2.71 .8 ±1.62 .5 ±4.1 0.523
IL-6 [pg/μL] 2.2 ±1.23 .3 ±1.92 .8 ±1.13 .9 ±2.8 0.397
IL-8 [pg/μL] 6.5 ±1.46 .1 ±2.75 .2 ±2.76 .8 ±5.3 0.482
IL-10 [pg/μL] 1.4 ±0.91 .8 ±0.71 .6 ±1.13 .0 ±2.7 0.234
IL-12 [pg/μL] 1.1 ±0.61 .9 ±1.72 .1 ±1.42 .8 ±2.8 0.683
hsCRP [mg/dL] 1.1 ±1.21 .2 ±0.72 .3 ±2.82 .1 ±1.6 0.060
Fibrinogen [mg/dL] 345 ±94 371 ±122 382 ±65 361 ±83 0.790
Leukocytes [mg/dL] 7.1 ±1.47 .5 ±1.98 .1 ±1.47 .1 ±2.0 0.334
∗∗One-way ANOVA (analysis of variance) was used.
(AUC) and the predictive values are summarised in Table 4.
The cutoﬀs were selected by using DeLong and Clarke-
Pearson approach to provide the best statistical evidence
[23]. All patients with biomarker values higher than the
ascertained cutoﬀ points were considered as individuals with
neurological symptoms or as patients with unstable plaques.
Furthermore, multiple ROC analysis was performed for all
possible combinations of the above-described biomarkers.
Regarding neurological symptoms, the positive predictive
value (PPV) was quite low with around 50% for the
single factors and increased over 60% by their appropriate
combination. In contrast, the negative predictive value
(NPV)wassigniﬁcantlyhigherwithcurtlyunder70%forthe
individualbiomarkersandachievingupto80%forthefactor
grouping. With regard to the maximal PPV, combination of
MMP-7 and TIMP-1 achieved the highest value of 65.1%.
On the contrary to the neurological symptoms, PPV for
patients with vulnerable plaques was markedly higher with
76–79% for the single factor analysis. Their grouping led to
an increase for up to 86.4% using combined analysis with4 International Journal of Vascular Medicine
Table 3: Correlation analysis for various blood parameters.
MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 TIMP-1 TIMP-2
MMP-1 —
MMP-2 n.c. —
MMP-3 n.c. n.c. —
MMP-7 0.324∗∗∗ n.c. 0.264∗ —
MMP-8 n.c. n.c. n.c. n.c. —
MMP-9 n.c. n.c. n.c. n.c. 0.746∗∗∗ —
TIMP-1 0.195∗ n.c. n.c. 0.315∗∗∗ 0.225∗ n.c. —
TIMP-2 n.c. 0.531∗∗∗ n.c. n.c. n.c. n.c. 0.370∗∗∗ —
IL1-β n.c. n.c. n.c. n.c. n.c. 0.227∗ n.c. n.c.
IL-8 n.c. n.c. n.c. 0.328∗∗∗ 0.298∗∗ n.c. n.c. n.c.
IL-12 n.c. −0.287∗∗ n.c. n.c. n.c. n.c. n.c. n. c.
Leukocytes n.c. n.c. n.c. n.c. 0.275∗∗ 0.366∗∗∗ n.c. n.c.
CRP n.c. n.c. n.c. n.c. n.c. n.c. n.c. n.c.
Fibrinogen n.c. n.c. n.c. 0.274∗ 0.428∗∗∗ 0.418∗∗∗ n.c. n.c.
∗<0.05, ∗∗ <0.01, ∗∗∗ <0.001.
Table 4: Selected values of positive and negative predictive value (PPV, NPV) leading to improved prognosis of patients with either
neurological symptoms or plaque instability.
Neurol. symptoms Plaque instability
AUC∗ PPV∗ NPV∗ AUC∗ PPV∗ NPV∗
MMP-1 n.c. n.c. n.c. 0.691 79.6 55.3
MMP-7 0.639 49.3 69.2 0.615 76.2 45.8
MMP-9 0.637 52.5 67.5 0.674 79.2 50.9
TIMP-1 0.651 56.4 64.9 0.654 79.1 48.3
MMP-1 + MMP-7 n.c. n.c. n.c. n.c. n.c. n.c.
MMP-1 + MMP-9 n.c. n.c. n.c. n.c. n.c. n.c.
MMP-1 + TIMP-1 n.c. n.c. n.c. n.c. n.c. n.c.
MMP-7 + MMP-9 0.684 54.9 80.1 0.704 81.6 53.8
MMP-7 +TIMP-1 0.681 65.1 68.9 0.698 81.6 53.8
MMP-9 + TIMP-1 0.687 62.2 69.6 0.713 83.7 55.8
MMP-1 + MMP-7 + MMP-9 0.661 62.2 69.6 0.714 86.4 54.4
MMP-1 + MMP-7 + TIMP-1 0.655 61.4 68.4 0.727 79.7 59.5
MMP-1 + MMP-9 + TIMP-1 0.667 60.8 72.1 n.c. n.c. n.c.
MMP-7 + MMP-9 + TIMP-1 0.707 61.1 74.5 0.723 80.1 52.9
MMP-1 + MMP-7 + MMP-9 + TIMP-1 0.672 60.2 73.9 0.729 86.4 54.4
∗AUC: area under curve; only values with statistical signiﬁcance are shown; n.c.: no further increase in positive (PPV) and negative (NPV) predictive value.
MMP-1, -7, and -9. The NPV remained almost unchanged
independent of the combination used.
4. Discussion
Biomarkersforpreventionofstrokearepromisingdiagnostic
tool in medical praxis. Due to the heterogeneity of the
atherosclerotic lesions, however, single marker will never be
suﬃcient for reliable prediction of patients at increased risk
of stroke. Furthermore, the values of the biomarkers and
the cutoﬀ value at risk can markedly alternate between the
individual patients. So far only few studies have evaluated
the usefulness of multiple biomarkers and their overall asso-
ciation with neurological symptoms or plaque vulnerability,
especially concerning unstable carotid lesions.
FromthevariousMMPs,theirinhibitors,andtheinﬂam-
matoryfactorsanalysedinthisstudy,serumlevelsofMMP-1,
-7, -9, and TIMP-1 were signiﬁcantly increased in patients
with neurological symptoms and vulnerable plaques. All
these factors were already described being involved in the
degradation of extracellular matrix [5, 7, 10, 11, 24, 25].
Thus, they could reliably reﬂect unstable carotid plaques inInternational Journal of Vascular Medicine 5
patients at risk of stroke. Interestingly, diﬀerent biomarkers
can be related either to neurological symptoms or to plaque
instability [2, 17]. This is an important issue, because
many researchers often equate neurological symptoms with
plaque vulnerability. However, not all ischemic strokes are
caused by unstable plaques. Only 15–20% of all ischemic
strokes account for atherosclerotic carotid stenosis [5, 26].
Therefore, prevention of stroke on the basis of biomarker
evaluation in the blood of the concerned patients should
be related to plaque vulnerability. This is the reason for
the discrepancy between the individual biomarker in our
study related either to neurological symptoms or carotid
plaque stability. From our point of view, the markers that
show signiﬁcant diﬀerences between patients with stable
versus unstable plaques are of higher value compared to
biomarkers corresponding with symptoms. This was also the
reason why we have combined neurological symptoms and
plaque vulnerability together. Interestingly, various MMPs
and inﬂammatory factors could be associated with diﬀerent
clinical ﬁndings. MMP-1, -7, and TIMP-1 were associated
with either symptoms or plaque instability. In contrast,
MMP-9 seemed to be related mainly to the neurologi-
cal symptoms (Table 2). Regarding inﬂammatory factors,
increased levels of TNF-α and IL-6 were associated with
plaque instability, IL-10 only in the group of symptomatic
patients with unstable plaques. High sensitive CRP appeared
to be more related to neurological symptoms than to
plaque instability and ﬁbrinogen for both. Again, these data
conﬁrm the pathophysiological diﬀerences between patient
symptomatic and plaque vulnerability [2, 17]. Nevertheless,
our data demonstrated that whether the symptoms are
causedbyunstablecarotidplaquesoratheroscleroticchanges
in other vessels can also have common features that can
be reﬂected in the blood of patients at risk of stroke. This
assumptionwasfurtherconﬁrmedbythecorrelationanalysis
of the individual factors (Table 3).
Interestingly, independent of neurological symptom or
plaque instability, no statistically signiﬁcant diﬀerences
between patients with stable and unstable lesions were
observed for MMP-2 as described in some former studies
[13–15]. The reason for these discrepancies is that we have
characterised the plaques in accordance with Redgrave and
Rothwell [18, 19], looking eﬀectively for the true unstable
plaques. In contrast, the early studies graded the plaques
according to AHA classiﬁcation, assuming atherosclerotic
lesion type V as stable, type VI as unstable. But patients
with carotid lesions of type VI (plaques with thrombotic
deposits and haemorrhage) with thick ﬁbrous cap can still
be considered as stable. And plaques of type V with thin
ﬁbrous cup under 200μmo v e ral a r g en e c r o t i cc o r ec a nb e
considered as unstable.
Regarding inﬂammatory factors, no signiﬁcant diﬀer-
ences were observed between the groups, even if some
tendencies have been observed, especially for TNF-α,I L - 6 ,
IL-10, CRP, and ﬁbrinogen. However, it is to consider that
our patients had already an advanced stage of carotid artery
stenosis >70% and almost all of them were hypertensive. So,
the level of many of the inﬂammatory factors in blood of
ourpatientswasalreadyincreased,comparedtohealthyindi-
viduals. In addition, atherosclerotic lesions are frequently
accompanied by chronic inﬂammation. So, inﬂammatory
factors may correlate with advanced carotid stenosis, are,
however, not speciﬁc enough to detect vulnerable plaques
[25, 27].
The main goal of the study was to evaluate whether com-
bination of relevant biomarkers of advanced carotid lesions
might be better associated with neurological symptoms or
plaque vulnerability compared with single biomarkers. The
combination of selected biomarkers led indeed to increased
AUC and PPVs. Interestingly, high positive prediction could
be associated with plaque vulnerability for up to 86%
compared to only 65% regarding patient symptomatic.
In contrast, negative prediction was high for the clinical
symptoms with up to 80%, but the factor grouping did not
signiﬁcantly improve the NPV for patients with unstable
plaques, which was in the most cases between 50 and
60%, considering patients incorrectly as individuals at risk.
The problem of biomarkers is generally that they often
inﬂuence each other. So, if the level of one of them is
increased, the others are increased as well (see also Table 3).
The combination of such biomarkers, however, does not
necessarily lead to an increased predictivity over the analysis
of single factors. To establish a set of relevant biomarkers
for more reliable diagnosis of stroke, independent markers
are necessary to improve the overall sensitivity and especially
speciﬁcity [20]. Still, our data demonstrate that the use
of more than one biomarker better correlates with the
clinical ﬁndings and seems therefore to be superior to the
analysis of single factors. These results further conﬁrm our
assumptionthatmultivariateanalysesofrelevantbiomarkers
are necessary to reduce the risk of inaccurate diagnosis.
5. Conclusion
In summary, we evaluated various predictive biomarkers
and their combinations in patients with advanced carotid
stenosis in order to improve the concordance with clinical
ﬁndings such as neurological symptoms or/and unstable
plaques. Further experiments, especially large prospective
clinical studies, are necessary to evaluate the relevance of
such biomarkers. In addition, the proper cutoﬀ values have
to be accurately interpreted and carefully reevaluated before
they can be used in clinical praxis for, for example, reliable
prevention of patients at increased risk of stroke.
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